Here’s how analysts see AbbVie Inc. (NYSE:ABBV) after this past week.

January 20, 2018 - By Darrin Black

 Here's how analysts see AbbVie Inc. (NYSE:ABBV) after this past week.
Investors sentiment decreased to 0.85 in 2017 Q3. Its down 0.15, from 1 in 2017Q2. It worsened, as 55 investors sold AbbVie Inc. shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported.
Becker Capital Mgmt invested in 0.02% or 7,184 shares. Creative Planning accumulated 239,574 shares or 0.1% of the stock. Covington Investment Advisors Inc holds 1.03% or 30,836 shares in its portfolio. Fairview Investment Management Limited Liability has invested 0.02% in AbbVie Inc. (NYSE:ABBV). Boltwood Capital Mgmt reported 0.63% in AbbVie Inc. (NYSE:ABBV). Pillar Pacific Cap Mgmt Limited Liability Com owns 16,818 shares or 0.19% of their US portfolio. Healthcor Management L P has 2.94% invested in AbbVie Inc. (NYSE:ABBV). Alpine Woods Capital Ltd Liability accumulated 31,783 shares. Louisiana State Employees Retirement accumulated 0.42% or 99,500 shares. D Scott Neal accumulated 2,153 shares or 0.12% of the stock. Glenview Cap Mgmt Llc has 2.75% invested in AbbVie Inc. (NYSE:ABBV) for 5.34M shares. Nebraska-based Nelson Van Denburg & Campbell Wealth Management Grp Ltd Liability Corp has invested 0.61% in AbbVie Inc. (NYSE:ABBV). Edgar Lomax Va holds 0.84% or 133,333 shares. Manning & Napier Advsrs Limited Liability Company reported 0.19% of its portfolio in AbbVie Inc. (NYSE:ABBV). Legacy Private Com owns 33,902 shares.

Since July 31, 2017, it had 0 buys, and 8 selling transactions for $45.57 million activity. $21,127 worth of AbbVie Inc. (NYSE:ABBV) was sold by Gosebruch Henry O on Monday, July 31. Shares for $589,512 were sold by Michael Robert A. on Thursday, September 28. Another trade for 87,899 shares valued at $6.24M was sold by GONZALEZ RICHARD A. 87,040 shares were sold by RICHMOND TIMOTHY J., worth $8.57M on Monday, December 18. $705,655 worth of AbbVie Inc. (NYSE:ABBV) shares were sold by SALEKI-GERHARDT AZITA.

AbbVie Inc. (NYSE:ABBV) Ratings Coverage

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 11 have Buy rating, 1 Sell and 9 Hold. Therefore 52% are positive. Abbvie Inc had 71 analyst reports since July 21, 2015 according to SRatingsIntel. As per Thursday, November 16, the company rating was maintained by BMO Capital Markets. The rating was initiated by SunTrust on Wednesday, July 22 with “Buy”. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Sunday, October 29 by SunTrust. The rating was downgraded by Citigroup to “Neutral” on Monday, November 28. The rating was maintained by Jefferies on Friday, July 14 with “Buy”. Jefferies maintained it with “Buy” rating and $120.0 target in Thursday, January 4 report. The stock of AbbVie Inc. (NYSE:ABBV) earned “Buy” rating by TheStreet on Tuesday, August 11. The company was maintained on Monday, November 20 by Cowen & Co. Goldman Sachs downgraded the shares of ABBV in report on Monday, March 7 to “Buy” rating. The firm has “Hold” rating by BMO Capital Markets given on Wednesday, October 11. Below is a list of AbbVie Inc. (NYSE:ABBV) latest ratings and price target changes.

16/01/2018 Broker: Jefferies Rating: Buy New Target: $130.0 Maintain
04/01/2018 Broker: Jefferies Rating: Buy New Target: $120.0 Maintain
05/12/2017 Broker: Leerink Swann Rating: Buy New Target: $106.0 Maintain
20/11/2017 Broker: Cowen & Co Rating: Buy New Target: $105.0 Maintain
16/11/2017 Broker: BMO Capital Markets Rating: Market Perform Old Target: $66 New Target: $84 Maintain
29/10/2017 Broker: SunTrust Rating: Buy New Target: $105.0 Maintain
30/10/2017 Broker: Leerink Swann Rating: Outperform Old Target: $108 New Target: $107 Maintain
16/10/2017 Broker: SunTrust Rating: Buy New Target: $95.0 Maintain
11/10/2017 Broker: BMO Capital Markets Rating: Hold New Target: $66.0 Maintain
13/10/2017 Broker: Barclays Capital Rating: Equal-Weight Old Target: $6.00 New Target: $9.00 Maintain

The stock increased 0.80% or $0.83 during the last trading session, reaching $104.64. About 4.99M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since January 20, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has market cap of $167.05 billion. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It has a 25.42 P/E ratio. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Fool.com which released: “Here’s How AbbVie Inc. Crushed It in 2017” on December 23, 2017, also Nasdaq.com with their article: “AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for January 11, 2018” published on January 10, 2018, Investorplace.com published: “AbbVie Inc Dividend at Risk Amid Patent Protection Problems” on December 29, 2017. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Seekingalpha.com and their article: “Key events next week – healthcare” published on January 19, 2018 as well as Nasdaq.com‘s news article titled: “Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?” with publication date: January 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.